‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s 'Anti-Science' Vaccine Policies

Why It Matters

Kennedy’s anti‑vaccine stance threatens revenue streams for major pharma firms and could reshape public‑health funding priorities, prompting investors to reassess exposure to vaccine manufacturers.

Key Takeaways

• Kennedy questioned measles vaccine safety during outbreak
• COVID‑19 vaccines removed from routine schedule for children
• Pfizer Prevnar sales fell 4% YoY Q3 2025
• Abrysvo RSV shot plunged 22% in same quarter
• Vaccine market slowdown linked to policy controversy

Pulse Analysis

The clash between Pfizer’s leadership and the U.S. health secretary underscores a growing politicization of vaccine policy. While the FDA continues to endorse the safety and efficacy of its products, Kennedy’s public statements have introduced uncertainty that reverberates through supply chains, pricing negotiations, and market forecasts. Analysts note that the timing of policy shifts—such as the removal of COVID‑19 vaccines from pediatric guidelines—aligns with a measurable dip in sales across the sector, suggesting that regulatory tone can directly influence commercial performance.

Beyond immediate revenue impacts, the controversy raises strategic questions for pharmaceutical firms about diversification and risk mitigation. Companies like Pfizer are now weighing the benefits of expanding into non‑vaccine therapeutics, bolstering global market exposure, and investing in robust public‑relations campaigns to counteract misinformation. The broader industry trend points to a potential reallocation of R&D dollars toward areas less vulnerable to political swings, while still maintaining a pipeline capable of rapid response to future pandemics.

For investors and policymakers, the episode serves as a cautionary tale about the interplay between science, politics, and market dynamics. A sustained anti‑science narrative could erode public confidence, depress vaccination rates, and ultimately affect herd immunity, creating long‑term health and economic costs. Stakeholders must therefore monitor regulatory developments, track vaccine uptake metrics, and evaluate corporate strategies that balance scientific integrity with commercial resilience.